Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2020438 | 0.89 | KMT2A (0.71) | KMT2AMEN1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL4152010 | 0.88 | KMT2A (0.56) | KMT2AMEN1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL2021172 | 0.88 | KMT2A (0.70) | KMT2AMEN1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL6537339 | 0.87 | KMT2A (0.68) | KMT2AMEN1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL440425 | 0.87 | KMT2A (0.68) | KMT2AMEN1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL6293263 | 0.87 | KMT2A (0.68) | KMT2AMEN1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL2719292 | 0.87 | KMT2A (0.68) | KMT2AMEN1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL4011505 | 0.87 | KMT2A (0.55) | KMT2AMEN1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL11244456 | 0.87 | MEN1 (0.68) | KMT2AMEN1MAPTLMNAHTT | |
| SCHEMBL6289957 | 0.87 | KMT2A (0.68) | KMT2AMEN1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11427582-B2 | Ligands selective to alpha 6 subunit-containing GABAA receptors and their methods of use | UWM RESEARCH FOUNDATION, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20210047322-A1 | LIGANDS SELECTIVE TO ALPHA 6 SUBUNIT-CONTAINING GABAA RECEPTORS AND THEIR METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-02-18 | — | — | US | disclosed |
| US-10865203-B2 | Ligands selective to alpha 6 subunit-containing GABAA receptors and their methods of use | UWM RESEARCH FOUNDATION, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| EP-3325479-B1 | LIGANDS SELECTIVE TO ALPHA 6 SUBUNIT-CONTAINING GABAA RECEPTORS AND THEIR METHODS OF USE | UWM RES FOUNDATION INC (US) | 2020-12-02 | — | — | EP | disclosed |
| US-10568888-B2 | Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors | VTV THERAPEUTICS LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190336506-A1 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC | 2019-11-07 | — | — | US | disclosed |
| US-10391097-B2 | Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors | VTV THERAPEUTICS LLC (US) | 2019-08-27 | — | — | US | disclosed |
| US-20180360839-A1 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS | TRANSTECH PHARMA, INC. | 2018-12-20 | — | — | US | disclosed |
| US-10085990-B2 | Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors | VTV THERAPEUTICS LLC (US) | 2018-10-02 | — | — | US | disclosed |
| EP-3325479-A1 | LIGANDS SELECTIVE TO ALPHA 6 SUBUNIT-CONTAINING GABAa RECEPTORS ANS THEIR METHODS OF USE | UWM Research Foundation, Inc. (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-1943234-A1 | TRIAZOLE COMPOUNDS AS LIPOXYGENASE INHIBITORS | Biolipox AB (SE) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007051982-A1 | TRIAZOLE COMPOUNDS AS LIPOXYGENASE INHIBITORS | BIOLIPOX AB (SE) | 2007-05-10 | — | — | WO | disclosed |
| EP-1243583-B1 | HETEROCYCLIC COMPOUNDS HAVING SULFONAMIDE GROUPS | EISAI CO LTD (JP) | 2005-09-28 | — | — | EP | disclosed |
| US-20050176712-A1 | Integrin expression inhibitor | EISAI CO., LTD. | 2005-08-11 | — | — | US | disclosed |
| US-6787534-B2 | SUBSTITUTED QUINOLINE AND ISOQUINOLINE ANTIANGIOGENIC AGENTS; SULFONYLUREAS | EISAI CO., LTD. (JP) | 2004-09-07 | — | — | US | disclosed |
| US-20040018192-A1 | Integrin expression inhibitors | EISAI CO., LTD. (JP) | 2004-01-29 | — | — | US | disclosed |
| US-20030144507-A1 | Sulfonamide-containing heterocyclic compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-07-31 | — | — | US | disclosed |
| EP-1258252-A1 | INTEGRIN EXPRESSION INHIBITORS | Eisai Co., Ltd. (JP) | 2002-11-20 | — | — | EP | disclosed |
| EP-1243583-A1 | HETEROCYCLIC COMPOUNDS HAVING SULFONAMIDE GROUPS | Eisai Co., Ltd. (JP) | 2002-09-25 | — | — | EP | disclosed |
| US-4343804-A | 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds | A. H. ROBINS COMPANY, INC. (US) | 1982-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176712-A1 | Integrin expression inhibitor | ITGB5, ITGB1, ITGB2 | KMT2A 2009/4885MEN1 2665/4885SMN1; SMN2 2639/4885 |
| US-20190336506-A1 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS | PDE4A, PDE4B, TNF | KMT2A 3800/4885MEN1 3490/4885SMN1; SMN2 4826/4885 |
| US-20210047322-A1 | LIGANDS SELECTIVE TO ALPHA 6 SUBUNIT-CONTAINING GABAA RECEPTORS AND THEIR METHODS OF USE | GABRA6, HTR6, GABRD | KMT2A 3519/4885MEN1 3061/4885SMN1; SMN2 1894/4885 |
| US-20180360839-A1 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | KMT2A 4100/4885MEN1 4610/4885SMN1; SMN2 4458/4885 |
| US-10568888-B2 | Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors | PDE4A, PDE4B, TNF | KMT2A 3800/4885MEN1 3490/4885SMN1; SMN2 4826/4885 |
| US-11427582-B2 | Ligands selective to alpha 6 subunit-containing GABAA receptors and their methods of use | GABRA6, HTR6, GABRD | KMT2A 3519/4885MEN1 3061/4885SMN1; SMN2 1894/4885 |
| US-10085990-B2 | Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors | PDE4A, TNF, PDE4B | KMT2A 4098/4885MEN1 4616/4885SMN1; SMN2 4506/4885 |
| US-10391097-B2 | Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors | PDE4A, PDE4B, PDE4C | KMT2A 4100/4885MEN1 4610/4885SMN1; SMN2 4458/4885 |
| US-10865203-B2 | Ligands selective to alpha 6 subunit-containing GABAA receptors and their methods of use | GABRA6, HTR6, GABRD | KMT2A 3756/4885MEN1 3268/4885SMN1; SMN2 2208/4885 |
| US-20040018192-A1 | Integrin expression inhibitors | ITGB1, ITGB4, ITGB5 | KMT2A 2523/4885MEN1 3218/4885SMN1; SMN2 2404/4885 |
| US-20030144507-A1 | Sulfonamide-containing heterocyclic compounds | SLC5A2, SLC5A1, CBR3 | KMT2A 1187/4885MEN1 3262/4885SMN1; SMN2 1987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.